January 8, 2018 / 12:09 PM / 10 months ago

BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts

Jan 8 (Reuters) - Aclaris Therapeutics Inc:

* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS

* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS

* ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​

* ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below